BidaskClub downgraded shares of Radius Health (NASDAQ:RDUS) from a sell rating to a strong sell rating in a report released on Thursday morning.

Several other brokerages have also commented on RDUS. Maxim Group reiterated a positive rating on shares of Radius Health in a research note on Friday, September 29th. They noted that the move was a valuation call. Zacks Investment Research lowered shares of Radius Health from a hold rating to a sell rating in a research note on Wednesday, October 4th. Goldman Sachs Group reiterated a neutral rating and set a $45.00 price target on shares of Radius Health in a research note on Friday, October 6th. Jefferies Group reiterated a hold rating and set a $38.00 price target (up from $34.00) on shares of Radius Health in a research note on Wednesday, August 9th. Finally, Cantor Fitzgerald reiterated a buy rating and set a $58.00 price target on shares of Radius Health in a research note on Friday, November 3rd. Three investment analysts have rated the stock with a sell rating, four have assigned a hold rating and five have given a buy rating to the company’s stock. The stock currently has a consensus rating of Hold and a consensus target price of $48.00.

Shares of Radius Health (NASDAQ RDUS) traded up $4.19 on Thursday, hitting $31.60. 3,177,683 shares of the stock were exchanged, compared to its average volume of 974,338. Radius Health has a fifty-two week low of $24.66 and a fifty-two week high of $49.39. The company has a current ratio of 12.87, a quick ratio of 12.79 and a debt-to-equity ratio of 0.53.

Radius Health (NASDAQ:RDUS) last announced its quarterly earnings data on Thursday, November 2nd. The biopharmaceutical company reported ($1.31) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.28) by ($0.03). The firm had revenue of $13.50 million for the quarter, compared to analyst estimates of $6.90 million. During the same quarter last year, the firm earned ($1.07) EPS. equities analysts expect that Radius Health will post -5.57 EPS for the current year.

In other Radius Health news, VP Brent Hatzis-Schoch acquired 1,778 shares of the company’s stock in a transaction on Friday, November 10th. The shares were bought at an average cost of $28.09 per share, for a total transaction of $49,944.02. Following the completion of the purchase, the vice president now owns 2,278 shares in the company, valued at approximately $63,989.02. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Growth N. V. Biotech acquired 50,000 shares of the company’s stock in a transaction on Tuesday, September 12th. The stock was acquired at an average price of $35.42 per share, for a total transaction of $1,771,000.00. Following the completion of the purchase, the insider now owns 5,348,799 shares of the company’s stock, valued at approximately $189,454,460.58. The disclosure for this purchase can be found here. Over the last 90 days, insiders acquired 367,678 shares of company stock worth $11,746,498. 15.00% of the stock is currently owned by company insiders.

A number of hedge funds and other institutional investors have recently bought and sold shares of RDUS. Teachers Advisors LLC increased its stake in Radius Health by 4.4% in the first quarter. Teachers Advisors LLC now owns 54,024 shares of the biopharmaceutical company’s stock valued at $2,088,000 after purchasing an additional 2,289 shares during the period. Russell Investments Group Ltd. increased its stake in Radius Health by 144.2% in the second quarter. Russell Investments Group Ltd. now owns 12,562 shares of the biopharmaceutical company’s stock valued at $568,000 after purchasing an additional 7,417 shares during the period. Sei Investments Co. increased its stake in Radius Health by 27.7% in the second quarter. Sei Investments Co. now owns 3,180 shares of the biopharmaceutical company’s stock valued at $144,000 after purchasing an additional 690 shares during the period. TD Asset Management Inc. increased its stake in Radius Health by 68.0% in the second quarter. TD Asset Management Inc. now owns 145,970 shares of the biopharmaceutical company’s stock valued at $6,602,000 after purchasing an additional 59,100 shares during the period. Finally, Pictet Asset Management Ltd. increased its stake in Radius Health by 20.0% in the second quarter. Pictet Asset Management Ltd. now owns 641,388 shares of the biopharmaceutical company’s stock valued at $22,205,000 after purchasing an additional 106,849 shares during the period.

TRADEMARK VIOLATION WARNING: This piece was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece on another domain, it was stolen and reposted in violation of US and international copyright and trademark law. The original version of this piece can be accessed at https://www.thecerbatgem.com/2017/12/08/radius-health-rdus-lowered-to-strong-sell-at-bidaskclub.html.

About Radius Health

Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture.

Analyst Recommendations for Radius Health (NASDAQ:RDUS)

Receive News & Stock Ratings for Radius Health Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health Inc and related stocks with our FREE daily email newsletter.